Ambry Genetics Launches BRCA1/2: Single Genes and NGS Panel Offerings  
6/14/2013 10:20:06 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics announced today the launch of BRCA1 and BRCA2 analysis as part of their comprehensive cancer-testing menu. Two genes will be offered as a stand alone test comprising of full gene sequencing and deletion/duplication analyses in addition to being incorporated as part of multiple hereditary cancer panels that test cancer susceptibility genes using next-generation sequencing (NGS) technology. Additionally, Ambry Genetics is excited to launch a new high-risk hereditary breast cancer panel (BRCAplus) that simultaneously analyzes six clinically actionable genes: BRCA1, BRCA2, CDH1, PTEN, STK11 and TP53. These additions complement Ambry’s comprehensive menu of single gene offerings and NGS multi-gene panels designed for hereditary cancer syndromes.

Help employers find you! Check out all the jobs and post your resume.